156 related articles for article (PubMed ID: 37760951)
1. The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study.
Tsai CJ; Lin YC; Chen CY; Hung CH; Lin YC
Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760951
[TBL] [Abstract][Full Text] [Related]
2. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy.
Kim HA; Lee E; Park SY; Lee SS; Shin K
J Korean Med Sci; 2022 Aug; 37(33):e253. PubMed ID: 35996930
[TBL] [Abstract][Full Text] [Related]
4. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk of Common Orthopedic Surgeries for Patients with Rheumatic Diseases in Taiwan.
Hsieh MC; Koo M; Hsu CW; Lu MC
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422167
[No Abstract] [Full Text] [Related]
6. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink.
Edson-Heredia E; Zhu B; Lefevre C; Wang M; Barrett A; Bushe CJ; Cox A; Wu JJ; Maeda-Chubachi T
J Eur Acad Dermatol Venereol; 2015 May; 29(5):955-63. PubMed ID: 25352213
[TBL] [Abstract][Full Text] [Related]
7. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
[TBL] [Abstract][Full Text] [Related]
8. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
[TBL] [Abstract][Full Text] [Related]
9. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
[TBL] [Abstract][Full Text] [Related]
10. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
11. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.
Pérez-Plaza A; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Rivera R; Jiménez-Puya R; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1021-1028. PubMed ID: 28252811
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
14. The Skin May Clear But the Arthritis Won't Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy.
van Muijen ME; van Hal TW; Groenewoud HMM; van den Reek JMPA; de Jong EMGJ
Psoriasis (Auckl); 2020; 10():29-37. PubMed ID: 33117661
[TBL] [Abstract][Full Text] [Related]
15. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
16. Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry.
Michelena X; López-Medina C; Erra A; Juanola X; Font-Ugalde P; Collantes E; Marzo-Ortega H
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597989
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.
Ahmed N; Prior JA; Chen Y; Hayward R; Mallen CD; Hider SL
Clin Rheumatol; 2016 Dec; 35(12):3069-3073. PubMed ID: 27485152
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
19. Does biologic therapy impact the development of PsA among patients with psoriasis?
Meer E; Merola JF; Fitzsimmons R; Love TJ; Wang S; Shin D; Chen Y; Xie S; Choi H; Zhang Y; Scher JU; Ritchlin CT; Gelfand JM; Ogdie A
Ann Rheum Dis; 2022 Jan; 81(1):80-86. PubMed ID: 34615637
[TBL] [Abstract][Full Text] [Related]
20. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
